Learning, speech, movement and behaviour
Speech delay is the most commonly reported early sign. Support needs range from none to intellectual disability; autism traits, ADHD and anxiety are over-represented, and there is a raised risk of psychosis in adulthood.
Speech is the classic early sign. Many parents report first words late, and a specific difficulty planning the movements for speech (childhood apraxia of speech). Speech and language therapy - started early - makes a large practical difference.
Learning. Some children need no support; many need help with reading, and maths is often particularly hard (a "non-verbal learning difficulty" pattern is often described). Intellectual disability occurs in a minority and is usually mild when present.
Movement. Low muscle tone (hypotonia) and clumsy, uncoordinated movement are common in early childhood and usually improve with physiotherapy.
Behaviour and mental health. Autism spectrum traits, ADHD, anxiety and obsessive-compulsive features are more common than in the general population. In adolescence and adulthood there is a genuinely raised risk of psychosis/schizophrenia - not a certainty, but a reason to take a first episode of psychosis in a carrier seriously and to know the early warning signs.
The practical point: developmental paediatric review, speech therapy, occupational therapy, educational support (an individualised education plan) and mental-health watchfulness are the main "treatments" here. None of them are optional extras - they are where most of the benefit lies.
Freshest finding: A source describes a new or expanded observation: “Discussion Herein, we described a 24-year-old proband with moderate DD/ID, language delay, cryptorchidism, hypotonia, behavioral abnormalities, sexual dysfunction, dense hair, craniofacial anomalies, allergic purpura and eczema, and drug allergies caused by a novel de novo splicing variant, c.1496 +”
Reported neurodevelopmental profile
| Domain | Typical findings |
|---|---|
| Motor | Hypotonia in infancy, delayed walking, clumsiness/dyspraxia |
| Speech | Late first words, apraxia of speech, expressive > receptive language problems |
| Cognition | Full-scale IQ often low-normal to mildly impaired; non-verbal learning and maths especially affected |
| Autism | Reported in roughly 1 in 5-10 carriers in clinic-based series; 17q12 deletion is a recurrent ASD-associated CNV |
| Attention | ADHD and inattentive features common |
| Emotional | Anxiety, obsessive-compulsive features, behavioural difficulty in a minority |
| Psychiatric (adult) | Raised risk of schizophrenia-spectrum illness; absolute risk remains low |
| Epilepsy | Less common (~1 in 10), various seizure types |
| Brain imaging | Often normal; non-specific white-matter or cerebellar findings reported |
Evidence caveats
Neurodevelopmental figures are the least reliable in this condition, because ascertainment differs so much between renal-clinic cohorts (milder neurodevelopment) and developmental-clinic cohorts (milder renal). When the analysis shows a gene-phenotype link with low corroboration, treat it as a hypothesis generated by the collected corpus, not a finding.
What helps (as described by families and clinicians)
Early intervention programmes; speech therapy with a motor-speech approach; occupational therapy for fine motor and sensory issues; educational accommodations (extra time, written instructions, maths support); occupational/vocational support in adulthood; and explicit mental-health review at the adolescent-to-adult transition, which is where care tends to fall through the gap.
What the corpus says, by the numbers
- learning, speech and behaviour - mentioned in 201 collected documents (8195 mentions).
Latest evidence in the collected corpus
New observation reported: Discussion Herein, we described a 24-year-old proband with moderate DD/ID, language delay, cryptorchidism, hyp…
A source describes a new or expanded observation: “Discussion Herein, we described a 24-year-old proband with moderate DD/ID, language delay, cryptorchidism, hypotonia, behavioral abnormalities, sexual dysfunction, dense hair, craniofacial anomalies, allergic purpura and eczema, and drug allergies caused by a novel de novo splicing variant, c.1496 +”
“Discussion Herein, we described a 24-year-old proband with moderate DD/ID, language delay, cryptorchidism, hypotonia, behavioral abnormalities, sexual dysfunction, dense hair, craniofacial anomalies, allergic purpura and eczema, and drug allergies caused by a…”corroboration 1 · confidence 97% · updated 2026-11-14 · source
New observation reported: This is the first report on an inherited copy number variation in these self-limiting fever-sensitive epilepsy…
A source describes a new or expanded observation: “This is the first report on an inherited copy number variation in these self-limiting fever-sensitive epilepsy syndromes, potentially revealing a novel pathomechanism involved in familial FS and GEFS+.”
“This is the first report on an inherited copy number variation in these self-limiting fever-sensitive epilepsy syndromes, potentially revealing a novel pathomechanism involved in familial FS and GEFS+.”corroboration 1 · confidence 97% · updated 2026-11-14 · source
New observation reported: This overlap implies a statistically significant overrepresentation of ASD-risk SFARI genes among HI genes in …
A source describes a new or expanded observation: “This overlap implies a statistically significant overrepresentation of ASD-risk SFARI genes among HI genes in both novel ( p = 2.74 × 10 −4 ) and all NDD-risk regions ( p = 4.6 × 10 −5 ) identified in this study.”
“This overlap implies a statistically significant overrepresentation of ASD-risk SFARI genes among HI genes in both novel ( p = 2.74 × 10 −4 ) and all NDD-risk regions ( p = 4.6 × 10 −5 ) identified in this study.”corroboration 1 · confidence 97% · updated 2026-11-14 · source
New observation reported: 22 and Trost et al., 23 and also detected an enrichment of ASD-risk genes in the list of qDSGs ( p = 1.72 × 10…
A source describes a new or expanded observation: “22 and Trost et al., 23 and also detected an enrichment of ASD-risk genes in the list of qDSGs ( p = 1.72 × 10 −4 ) and also in the subset of those genes that are in novel CNV regions reported in this study ( p = 3.68 × 10 −3 ).”
“22 and Trost et al., 23 and also detected an enrichment of ASD-risk genes in the list of qDSGs ( p = 1.72 × 10 −4 ) and also in the subset of those genes that are in novel CNV regions reported in this study ( p = 3.68 × 10 −3 ).”corroboration 1 · confidence 97% · updated 2026-11-14 · source
New observation reported: Figure 2 Validation of NDD-risk for 162 qDSGs, 22 of them novel genes never associated before with risk for ND…
A source describes a new or expanded observation: “Figure 2 Validation of NDD-risk for 162 qDSGs, 22 of them novel genes never associated before with risk for NDD Validation of qDSG in NDD-risk regions found associated to autism in affected individuals from iHART and Decipher compared with control individuals from 1000 Genomes.”
“Figure 2 Validation of NDD-risk for 162 qDSGs, 22 of them novel genes never associated before with risk for NDD Validation of qDSG in NDD-risk regions found associated to autism in affected individuals from iHART and Decipher compared with control individuals…”corroboration 1 · confidence 97% · updated 2026-11-14 · source
New observation reported: Validation of NDD-risk for 162 qDSGs, 22 of them novel genes never associated before with risk for NDD Validat…
A source describes a new or expanded observation: “Validation of NDD-risk for 162 qDSGs, 22 of them novel genes never associated before with risk for NDD Validation of qDSG in NDD-risk regions found associated to autism in affected individuals from iHART and Decipher compared with control individuals from 1000 Genomes.”
“Validation of NDD-risk for 162 qDSGs, 22 of them novel genes never associated before with risk for NDD Validation of qDSG in NDD-risk regions found associated to autism in affected individuals from iHART and Decipher compared with control individuals from…”corroboration 1 · confidence 97% · updated 2026-11-14 · source
New observation reported: Through our results, we confirmed previous evidence that indicates that dosage variation is a key mechanism le…
A source describes a new or expanded observation: “Through our results, we confirmed previous evidence that indicates that dosage variation is a key mechanism leading to this type of disorder, since NDD-risk regions, both novel and previously reported, were significantly enriched for dosage-sensitive genes previously associated with risk for ASD and”
“Through our results, we confirmed previous evidence that indicates that dosage variation is a key mechanism leading to this type of disorder, since NDD-risk regions, both novel and previously reported, were significantly enriched for dosage-sensitive genes…”corroboration 1 · confidence 97% · updated 2026-11-14 · source
New observation reported: Deletions in the 2q37.3 region have been previously reported in affected individuals with autism 43 and other …
A source describes a new or expanded observation: “Deletions in the 2q37.3 region have been previously reported in affected individuals with autism 43 and other NDDs 44 , 45 but COPS8 had never been associated as a critical gene for this region.”
“Deletions in the 2q37.3 region have been previously reported in affected individuals with autism 43 and other NDDs 44 , 45 but COPS8 had never been associated as a critical gene for this region.”corroboration 1 · confidence 97% · updated 2026-11-14 · source
This entry is version 10. The analytical engine only appends the clearly-labelled “Latest evidence” section; the text above is curated and is not rewritten by the machine. Confidence 78% · last updated 2026-11-14 16:44